These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36126024)

  • 21. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
    Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of delaying prophylaxis against CMV in D+/R- solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease.
    San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martin-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM; ;
    J Infect; 2015 Nov; 71(5):561-70. PubMed ID: 26183297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor Cytomegalovirus Transmission Patterns in Solid Organ Transplant Recipients With Primary Infection.
    Hasing ME; Pang XL; Mabilangan C; Preiksaitis JK
    J Infect Dis; 2021 Mar; 223(5):827-837. PubMed ID: 32706857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Craig JC; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2008 Apr; (2):CD003774. PubMed ID: 18425894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation.
    Ekenberg C; da Cunha-Bang C; Lodding IP; Sørensen SS; Sengeløv H; Perch M; Rasmussen A; Gustafsson F; Wareham NE; Kirkby N; Kjaer J; Helleberg M; Reekie J; Lundgren JD
    Transpl Infect Dis; 2020 Apr; 22(2):e13252. PubMed ID: 31997565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients.
    Forlanini F; Dara J; Dvorak CC; Cowan MJ; Puck JM; Dorsey MJ
    Transpl Infect Dis; 2021 Apr; 23(2):e13504. PubMed ID: 33169931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using blood donors and solid organ transplant donors and recipients to estimate the seroprevalence of cytomegalovirus and Epstein-Barr virus in Canada: A cross-sectional study.
    Mabilangan C; Burton C; O'Brien S; Plitt S; Eurich D; Preiksaitis J
    J Assoc Med Microbiol Infect Dis Can; 2020 Oct; 5(3):158-176. PubMed ID: 36341316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transfusion-transmitted and community-acquired cytomegalovirus infection in seronegative solid organ transplant recipients receiving seronegative donor organs.
    Mabilangan C; Burton C; Nahirniak S; O'Brien S; Preiksaitis J
    Am J Transplant; 2020 Dec; 20(12):3509-3519. PubMed ID: 32428296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey From the Working Group of the European Society for Organ Transplantation.
    Grossi PA; Kamar N; Saliba F; Baldanti F; Aguado JM; Gottlieb J; Banas B; Potena L
    Transpl Int; 2022; 35():10332. PubMed ID: 35812158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients.
    Freeman RB; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Heaton N;
    Transplantation; 2004 Dec; 78(12):1765-73. PubMed ID: 15614149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
    da Cunha-Bang C; Sørensen SS; Iversen M; Sengeløv H; Hillingsø JG; Rasmussen A; Mortensen SA; Fox ZV; Kirkby NS; Christiansen CB; Lundgren JD
    Scand J Infect Dis; 2011 May; 43(5):360-5. PubMed ID: 21306196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Area-Level Social Deprivation and Cytomegalovirus Seropositivity at the Time of Solid Organ Transplant.
    Abidi MZ; Lopez R; Arrigain S; Weinberg A; Kaplan B; McAdams-DeMarco M; Schold JD; Erlandson KM
    JAMA Netw Open; 2024 Oct; 7(10):e2437878. PubMed ID: 39374014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA; Brennan DC; Saeed MJ; Fraser VJ; Olsen MA
    Clin Transplant; 2016 Apr; 30(4):435-44. PubMed ID: 26841129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients.
    Fisher CE; Alexander J; Bhattacharya R; Rakita RM; Kirby KA; Boeckh M; Limaye AP
    Transpl Infect Dis; 2016 Jun; 18(3):372-80. PubMed ID: 27004439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.
    Suresh S; Lee BE; Robinson JL; Akinwumi MS; Preiksaitis JK
    Pediatr Transplant; 2016 Nov; 20(7):970-980. PubMed ID: 27565955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C; Preiksaitis JK; Cervera C;
    Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.